CellGenix registers FDA Drug Master Files for ex-vivo CellGro® TNF-a and GM-CSF

16-Jun-2005

CellGenix has registered two new drug master files for TNF-a and GM-CSF. After filing a DMF for IL-4, this contributes further to the strategy of producing highest quality cytokines for the use in clinical ex-vivo cell culturing in connection with cell processing kits. As proposed in the new USP chapter 1043, which became effective on April 1, a DMF cross reference is recommended for all ancillary materials used in clinical cell therapy.

Together with further quality and safety features, like animal-derived-free raw materials or batch-specific certificates-of-analysis, CellGenix´ ex-vivo grade cytokines fulfil all major recommendations given in USP 1043.

The cytokines are produced under cGMP-conditions, expressed in E-coli and no animal derived raw materials are used in the production or purification process. TNF-a and GM-CSF are intended for ex-vivo use only. Batch-specific Certificates of Analysis are issued and sent with each delivery.

CellGenix has filed these two DMFs which enable an investigator, upon written approval of CellGenix, to cross-reference either DMF in their own sponsored IND-application using ex-vivo processed cells in clinical research.

Other news from the department research and development

Most read news

More news from our other portals

Fighting cancer: latest developments and advances